ANI Pharmaceuticals Inc (ANI) develops, manufactures, and distributes generic and branded prescription pharmaceuticals including treatments for rare diseases. As of December 2025, the company had a commercial portfolio of more than 120 products with applications in various disease conditions. It offers products in varied dosage forms that include liquids, tablets, capsules, injectables, topicals, powder and enema products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focus on developing and expanding a diversified portfolio of branded, rare disease, and generic pharmaceutical products. The company invests in formulation development, lifecycle management, and regulatory approval processes to strengthen its pipeline and sustain long-term growth. Its research efforts emphasize niche and complex generics, as well as specialty and rare disease therapies such as Cortrophin Gel and ophthalmology products. ANI also enhances its pipeline through product acquisitions, licensing arrangements, and strategic partnerships. By leveraging in-house development capabilities and regulatory expertise, the company aims to accelerate product launches, improve therapeutic offerings, and address unmet patient needs while supporting sustainable revenue expansion. As of December 2025, the company owned six US patents, as well as pending patent applications relating to Cortrophin Gel. In FY2025, the company spent US$51.6 million, which as a percentage of revenue stood at 5.8% and grew 15.9% YoY.